Related content

User Experience with an Oral Contraceptive Containing Ethinylestradiol 30g and Drospirenone 3mg (Yasmin ® ) in Clinical Practice

By Schultz-Zehden Beate  

Treatments in Endocrinology, Vol. 5, Iss. 4, 2006-01 ,pp. : 251-256

Adis International

Access to resources Recommend Favorite

A Comparison of the Cycle Control, Safety, and Efficacy Profile of a 21-Day Regimen of Ethinylestradiol 20g and Drospirenone 3mg with a 21-Day Regimen of Ethinylestradiol 20g and Desogestrel 150g

By Gruber Doris M.  

Treatments in Endocrinology, Vol. 5, Iss. 2, 2006-01 ,pp. : 115-121

Adis International

Access to resources Recommend Favorite

Influence of a new oral contraceptive with drospirenone on lipid metabolism

By Taneepanichskul Surasak   Phupong Vorapong  

Gynecological Endocrinology, Vol. 23, Iss. 6, 2007-06 ,pp. : 347-350

Informa Healthcare

Access to resources Recommend Favorite

Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 µg ethinyl estradiol and 3 mg drospirenone

By Milsom I.   Lete I.   Bjertnaes A.   Rokstad K.   Lindh I.   Gruber C.J.   Birkhäuser M.H.   Aubeny E.   Knudsen T.   Bastianelli C.  

Human Reproduction, Vol. 21, Iss. 9, 2006-09 ,pp. : 2304-2311

Oxford University Press

Access to resources Recommend Favorite

Ethinylestradiol/Drospirenone: A Review of its Use as an Oral Contraceptive

By Keam S.J.   Wagstaff A.J.  

Treatments in Endocrinology, Vol. 2, Iss. 1, 2003-01 ,pp. : 39-61

Adis International

Access to resources Recommend Favorite